A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

To be able to join this study, you would need to be an adult, aged 18 or older, who has recently been diagnosed with a specific type of DLBCL and has not had any treatment for it yet. Your doctor would need to confirm that your type of lymphoma fits the study criteria, including if it's 'CD20-positive'. You would also need to be generally well enough to take part, as assessed by a common health check. An important part of checking if you can join is a special blood test that looks for 'circulating tumour DNA' – if this test shows you are 'high-risk', you might be a good fit.

Other health checks are also needed. For instance, your heart needs to be strong enough, and other blood tests would show that your blood is healthy enough to start treatment. You would also need to have at least one measurable area of lymphoma that doctors can track. For women who could become pregnant and men who could father a child, it's important to be using effective contraception during the study. You would also need to be expected to live for at least six more months.

However, some things would mean you couldn't join. For example, if you have a different type of lymphoma that doesn't fit the study's focus, or if you have certain other health conditions that would make the treatment unsafe for you. If you have any allergies to the drugs used in the study, or if you've already had certain strong anti-cancer drugs, you wouldn't be able to participate.

If you decide to take part in this study, you will receive regular medical care and tests. This will involve appointments at the hospital or clinic, where you will have examinations, blood tests, and scans (like PET/CT scans) to monitor your health and how the treatment is working. You will receive the study medications, which include Glofitamab and the standard R-CHOP drugs, given through injections or drips. The doctors and nurses will explain exactly how these are given and how often.

The study involves several treatment cycles. During this time, you'll have ongoing assessments to check for any side effects and to see how your lymphoma is responding. After your main treatment period, there will be follow-up appointments to continue monitoring your health over a longer period. The total duration of your participation, including follow-up, will be explained by the study team, but it typically lasts for many months or even longer.